Title:The Role of Non-coding RNAs in Alzheimer’s Disease: Pathogenesis,
Novel Biomarkers, and Potential Therapeutic Targets
Volume: 23
Issue: 6
Author(s): Othman Saleh*, Khaled Albakri, Abdalrahmn Altiti, Iser Abutair, Suhaib Shalan, Omar Bassam Mohd, Ahmed Negida, Gohar Mushtaq and Mohammad A. Kamal
Affiliation:
- Faculty of Medicine, The Hashemite University, Zarqa, Jordan
Keywords:
Beta-amyloid, Alzheimer's disease, lncRNA, pathogenesis, biomarkers, AD pathophysiology.
Abstract: Long non-coding RNAs (IncRNAs) are regulatory RNA transcripts that have recently been
associated with the onset of many neurodegenerative illnesses, including Alzheimer's disease (AD).
Several IncRNAs have been found to be associated with AD pathophysiology, each with a distinct
mechanism. In this review, we focused on the role of IncRNAs in the pathogenesis of AD and their
potential as novel biomarkers and therapeutic targets. Searching for relevant articles was done using
the PubMed and Cochrane library databases. Studies had to be published in full text in English in order
to be considered. Some IncRNAs were found to be upregulated, while others were downregulated.
Dysregulation of IncRNAs expression may contribute to AD pathogenesis. Their effects manifest as
the synthesis of beta-amyloid (Aβ) plaques increases, thereby altering neuronal plasticity, inducing inflammation,
and promoting apoptosis. Despite the need for more investigations, IncRNAs could potentially
increase the sensitivity of early detection of AD. Until now, there has been no effective treatment
for AD. Hence, InRNAs are promising molecules and may serve as potential therapeutic targets.
Although several dysregulated AD-associated lncRNAs have been discovered, the functional characterization
of most lncRNAs is still lacking.
